Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Janssen Biotech gets rights to Pharmacyclics' PCI32765

Executive Summary

Johnson & Johnson’s Janssen Biotech Inc. (a division of Janssen Pharmaceutical Cos.) has licensed worldwide development and marketing rights to Pharmacyclics Inc.’s (cancer and immune-mediated disease therapeutics) PCI32765, a first-in-class Bruton’s tyrosine kinase inhibitor in Phase II for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and multiple myeloma.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Trial Collaborations

Related Companies